A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 476 participants.

Also called NCT04252287

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 476 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04252287
Other papers using this trial's data
  • Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure JACC. Heart failure, 2023-11 DOI, PubMed 37498273
  • Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin JACC. Heart failure, 2024-04 DOI, PubMed 38385941
  • Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Trial Journal of cardiac failure, 2023-06 DOI, PubMed 37040839
  • The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial Nature medicine, 2022-04 DOI, PubMed 35228753, PMC9018422 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04252287. Randomized; double masking; primary purpose treatment. Start 2020-03-10 (actual); primary completion 2021-11-09 (actual). Results posted on 2023-01-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
Acronym
CHIEF-HF
Condition
Heart Failure
Intervention (Drug)
Canagliflozin 100 mg
Intervention (Drug)
Placebo
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct04252287
Content hash
cbc223a1b653696262e51439bd04845f6bd13d5a44739cc0c6b1907e5416012e